Hyperammonaemia in patients with chronic obstructive pulmonary disease and obesity: association mechanisms, detection rate and correction

Cover Page

Cite item

Full Text

Abstract

Chronic obstructive pulmonary disease (COPD) is a world-wide problem. It is characterized by comorbidity. Among the numerous comorbidity obesity is considered. The common pathogenetic factors cause the more severe course of COPD. Obesity is a complex metabolic condition affecting many physiological systems, in particular, the metabolic liver affection is developing in the type of non-alcoholic liver disease. In patients with different stages of non-alcoholic liver disease detoxification function is reduced. Toxic ammonia does not convert in urea. Ammonia begins to affect the whole organism.

Aim. To identify the frequency of hyperammonemia in patients with COPD and obesity, to analyze the degree of its influence on the COPD course and the quality of patients life, to assess the possibility of hyperammonemia correction with L-ornithine L-aspartate (LOLA).

Materials and methods. The study included 50 patients with non-acute COPD (GOLD 2), Group D, «phenotype with frequent exacerbations», central-type obesity. At the 1st stage of the investigation, COPD course was evaluated, specific evaluation tests (mMRC, CCQ, CAT, SGRQ, SF-36) were used, the biochemical blood test was performed, hyperammoniemia was detected on a Pocket Chem BA PA-4140, and Number Connecting Test was performed. In the 2nd stage of the investigation, all patients were prescribed a course of treatment with LOLA and after 4 weeks the estimated parameters were compared in dynamics.

Results. After 4 weeks, comparative analysis showed reliable positive dynamics of subjective assessment of weakness, 2 scales of SGRQ questionnaire, all scales of SF-36 questionnaire, as well as reliable reduction of ammonia level by 18.26 μmol/l, normal value of Number Connecting Test.

Conclusion. Detection of hyperammoniemia in patients with COPD and obesity and its correction with LOLA seems rational in order to reduce toxic effects of ammonia on organs and systems in this category of patients.

About the authors

S. A. Kozhevnikova

Burdenko Voronezh State Medical University

Author for correspondence.
Email: kozhevnikova_s_a@mail.ru
ORCID iD: 0000-0001-9497-2916

к.м.н., доц. каф. терапевтических дисциплин ИДПО

Russian Federation, Voronezh

L. V. Tribuntseva

Burdenko Voronezh State Medical University

Email: kozhevnikova_s_a@mail.ru
ORCID iD: 0000-0002-3617-8578

к.м.н., доц. каф. терапевтических дисциплин ИДПО

Russian Federation, Voronezh

A. V. Budnevsky

Burdenko Voronezh State Medical University

Email: kozhevnikova_s_a@mail.ru
ORCID iD: 0000-0002-1171-2746

д.м.н., проф., зав. каф. факультетской терапии, проректор по научно-инновационной деятельности

Russian Federation, Voronezh

References

  1. Глобальная стратегия диагностики, лечения и профилактики хронической обструктивной болезни легких. Доступно по ссылке: https://goldcopd.org/ (ссылка активна на 01.12.2019) [Global Initiative for Chronic Obstructive Lung Disease, 2019 report (GOLD, 2019). Available at: https://goldcopd.org/ (assessed 01.12.2019)].
  2. Самулеева Ю.В., Задионченко В.С., Ли В.В., Адашева Т.В., Саморукова Е.И., Пихлак А.Э. и др. Ожирение и метаболические нарушения у больных хронической обструктивной болезнью легких: возможности фенотипирования. Пульмонология. 2014;(5):32-8 [Samuleeva YuV, Zadionchenko VS, Li VV, Adasheva TV, Samorukova EI, Pikhlak AE, et al. Obesity and metabolic disorders in COPD patients: opportunities for phenotyping. Russian Pulmonology. 2014;(5):32-8 (In Russ.)]. doi: 10.18093/0869-0189-2014-0-5-32-38
  3. James BD, Jones A, Trethewey RE, Evans RA. Obesity and metabolic syndrome in COPD: is exercise the answer? Chron Respir Dis. 2017. doi: 0.1177/1479972317736294
  4. Lam KB, Jordan RE, Jiang CQ, Thomas GN, Miller MR, Zhang WS, et al. Airflow obstruction and metabolic syndrome. The Guangzhou Biobank Cohort Study. Eur Respir J. 2010;35:317-23. doi: 10.1183/09031936.00024709
  5. Бельснер М.С., Игнатова Г.Л., Блинова Е.В., Дроздов И.В., Антонов В.Н. Функция внешнего дыхания у больных тяжелой хронической обструктивной болезнью легких в сочетании с ожирением. Уральский медицинский журнал. 2014;4(118):85-7 [Belsner MS, Ignatova GL, Blinova EV, Drozdov IV, Antonov VN. Pulmonary function n patients with severe chronic obstructive pulmonary disease and obesity. Uralskij Medicinskij Zhurnal. 2014;4(118):85-7 (In Russ.)].
  6. Павленко О.А. Ожирение как фактор риска неалкогольной жировой болезни печени. Альманах клинической медицины. 2015;(1):60-6 [Pavlenko OA. Obesity as risk factor for non-alcoholic liver disease Almanax Klinicheskoj Mediciny. 2015;(1):60-6 (In Russ.)].
  7. Мусин А.Г., Муталова Э.Г., Нигматуллина А.Э., Константинова Е.Е., Мусина Ф.С., Насибуллин И.М. Современные аспекты механизмов фиброгенеза в печени. Медицинский вестник Башкортостана. 2014;9(3):95-9 [Musin AG, Mutalova EG, Nigmatullina AE, Konstantinova EE, Musina FS, Nasibullin IM. Actual aspects of fibrogenesis mechanisms in the liver. Medicinskij Vestnik Bashkortostana. 2014;9(3):95-9 (In Russ.)].
  8. Циммерман Я.С. Печеночная энцефалопатия: дефиниция, этиология, факторы патогенеза, клиника, методы диагностики и лечения. Гастроэнтерология Санкт-Петербурга. 2017;(2):68-75 [Cimmerman YaS. Hepatic encephalopathy: definition, etiology, pathogenesis factors, clinic, diagnostic and treatment methods. Gastroenterologiya Sankt-Peterburga. 2017;(2):68-75 (In Russ.)].
  9. Jalan R, De Chiara F, Balasubramaniyan V, Andreola F, Khetan V, Malago M, et al. Ammonia produces pathological changes in human hepatic stellate cells and is a target for therapy of portal hypertension. J Hepatol. 2016;64(4):823-33. doi: 10.1016/j.jhep.2015.11.019
  10. Walker V. Severe hyperammonaemia in adults not explained by liver disease. Ann Clin Biochem. 2012;(49):214-28.
  11. Агеева Е.А., Алексеенко С.А. Опыт применения пероральной формы препарата L-орнитин-L-аспартат при гипераммониемии у больных с хроническими заболеваниями печени на доцирротической стадии. Клинические перспективы гастроэнтерологии, гепатологии. 2015;(6):24-6 [Ageeva EA, Alekseenko SA. Experience with the use of the oral form of the drug L-ornithine-L-aspartate with hyperammonemia in patients with chronic liver diseases in the pre-cirrhotic stage. Klinicheskie Perspektivy Gastroenterologii, Gepatologii. 2015;(6):24-6 (In Russ.)].
  12. Буеверов А.О., Богомолов П.О., Маев И.В., Мациевич М.В., Уварова О.В. Возможности терапевтической коррекции гипераммониемии и минимальной печеночной энцефалопатии у пациентов с хроническим гепатитом С на доцирротической стадии. Терапевтический архив. 2019;91(2):52-8 [Buyeverov AO, Bogomolov PO, Mayev IV, Matsievich MV, Uvarova OV. Possibilities of therapeutic correction of hyperammonemia and minimal hepatic encephalopathy in patients with chronic hepatitis C at the pre-cirrhotic stage. Therapeutic Archive. 2019;91(2):52-8 (In Russ.)]. doi: 10.26442/00403660.2019.02.000125
  13. Ермолова Т.В., Ермолов С.Ю., Сологуб Т.В., Карев В.Е., Добкес А.Л., Апресян А.Г. Нарушения портопеченочной гемодинамики при хронических заболеваниях печени на начальных стадиях фиброза и их коррекция. Фарматека. 2016;15:1-8 [Ermolova TV, Ermolov SYu, Sologub TV, Karev VE, Dobkes AL, Apresyan AG. Violations of portohepatic hemodynamics in chronic liver diseases in the initial stages of fibrosis and their correction. Farmateka. 2016;15:1-8 (In Russ.)].

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies